Publication
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerEndometrial Carcinomacivic_curation1.00
- cancerOvarian Carcinomacivic_curation1.00
- drugCamonsertibcivic_curation1.00
- drugLunresertibcivic_curation1.00
- geneCCNE1civic_curation1.00
- variantCCNE1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40169546
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCNE1 Amplification2 | ||||||||
| Camonsertib + LunresertibCombination | Endometrial Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID12762In endometrial carcinoma (EMCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500), with ~80% growth inhibition at low-dose comb… (full text at CIViC) PMID 40169546 · Xu et al., 2025 · Open in CIViC | civic |
| 〃 | Ovarian Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID12761In ovarian carcinoma (OVCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500). CCNE1 copy number correlates with synergy by MTT… (full text at CIViC) PMID 40169546 · Xu et al., 2025 · Open in CIViC | civic |